James Aloysius Brady - 28 Mar 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
28 Mar 2025
Net transactions value
$0
Form type
4
Filing time
28 Mar 2025, 16:45:00 UTC
Previous filing
30 Apr 2024
Next filing
29 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +100,000 $0.000000 100,000 28 Mar 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.